• Herbal Formula Science
• /
• v.32 no.3
• /
• pp.325-343
• /
• 2024

Objective : To understand how Chungsangboha-tang (CSBHT) is being utilized in clinical practice and research in Korea, clinical studies related to CSBHT published in domestic academic journals were analyzed. Methods : The search was conducted using the following six databases: Korean Traditional Knowledge Portal, Oriental Medicine Advanced Searching Integrated System, ScienceON, Research Information Sharing Service, Koreanstudies Information Service System, and The Journal of Internal Korean Medicine. After selecting relevant literature published before June 24, 2024, the studies were classified and analyzed according to their research design. Results : The final selection comprised 20 studies categorized as follows: 1 non-randomized controlled trial and 10 before-and-after studies in prospective clinical research, along with 7 case reports and 2 retrospective chart reviews in retrospective clinical studies. Among the 233 participants included in these studies, 169 had asthma, 53 had chronic cough, and 5 had chronic obstructive pulmonary disease. Additionally, other conditions reported included Churg-Strauss syndrome, pulmonary Langerhans cell histiocytosis, non-tuberculous mycobacterial pulmonary disease, bronchiectasis, and pulmonary hypertension. CSBHT was administered as a decoction in 13 studies, as granules in 6 studies, and both in one study. The most frequently used assessment tools were pulmonary function tests and quality of life evaluations. For safety assessment, liver function test results and adverse events were reported. Conclusion : To enhance the utilization of CSBHT in Korean medicine clinical practice, continuous accumulation of domestic clinical research is essential. Moreover, meticulously designed randomized controlled trials are necessary to elevate the level of evidence.

• The Journal of Internal Korean Medicine
• /
• v.29 no.1
• /
• pp.12-24
• /
• 2008

Background and Objective : Chungsangboha-tang (CSBHT) has analgesic, sedative, anti-convulsive and anti-histamine effects, so it alleviates the symptoms of asthma. For the comparison of anti-inflammatory effect(s) on CSBHT, PD098059 was used as a negative control. Materials and Methods : This study emphasized THP-1 cells, which had been well characterized as a human monocytic leukemic cell line. The cells resemble monocytes with respect to several criteria and can be differentiated into macrophage-like cells by treatment with PMA. By using the MTS assay, it was possible to prove the safety of CSBHT. Results : Results shows that the CSBHT did not affected cell survival within $10^{1}$ ng/ml to $10^{5}$ ng/ml. Especially, $10^{5}$ ng/ml CSBHT treated cells show 70% deduction of $TNF-{\alpha}$ gene expression against that of LPS treated group. Furthermore, $IL-1{\beta}$, IL-6, IL-8, IL-10 and $TNF-{\alpha}$ levels are down-regulated when treated with CSBHT with concentrations up to 100 ug/ml on monocyte-derived macrophages. Interestingly, CSBHT-treated samples showed that overall transcriptional activities were down-regulated to 20% of that of PD098059 ($TNF-{\alpha}$ inhibitor). At protein level, the expression of $TNF-{\alpha}$ showed similar results as that of transcriptional activity. Results show that the protein level decreased more in the CSBHT-treated group (487 ${\pm}$ 87 pg/ml) than in the LPS-treated group (703 ${\pm}$ 103 pg/ml). In addition, the protein level of IL-8 in the CSBHT treated-group (9.84 ${\pm}$ 3.28 ng/ml) decreased similar as the expression of the control and PD098059-treated groups. Conclusion : CSBHT affects immune response, especially allergic responses and suppression of inflammatory reaction. The results provide us an alternative way to care for clinical inflammatory diseases, not only asthma but also the other possible general inflammatory and allergic diseases.

• Journal of Physiology & Pathology in Korean Medicine
• /
• v.16 no.4
• /
• pp.801-809
• /
• 2002

CSBHT is known to improve immunological response in mice and humans. In this study, CSBHT effect was examined in the context of CD4+ T cells' survival and TCR/CD3 induced activation responses. Spleen cells from 8 week BALB/c mice were cultured in CSBHT containing medium without activation for 24, 48 hr. The MTS assay and revealed that CSBHT did not stimulate spleen lymphocytes as mitogen. Spleen lymphocytes were treated with anti-CD3e/anti-CD28 antibodies for 48hr. Flow cytometry revealed that activity of T cell decreased with CSBHT concentration. CD4+ T cells were isolated and cultured ,in CSBHT containing medium for 48 hr. CSBHT did not affect survival of sorted CD4+ T cells without any involvement of APC. In order to evaluate the direct effect of CSBHT on helper T cells's proliferative capacity prior to activation, CD4+ T cells are isolated after 24hr of culture in CSBHT containing medium and activated with and without anti-CD3e/anti-CD28 activation for 48hr. A higher level of CD69 was observed in 1 ㎍/㎖ of CSBHT treatment than control using flow cytometry. But low CD69 expression was observed in 5㎍/㎖ of CSBHT treatment. Expression of mRNA for cytokines in CD4+ T cell revealed that IL-2 expression was increased in 1 ㎍/㎖. The expression of IL-2R α, INF- γ were increased with concentration. On the other hand mRNA of IL-4 was decreased in dose dependent manner. Results suggest that CSBHT may be desirable for CD4+ T cell's activity in immune responses. Further more, CSBHT may relatively activate Th1 and inactivate Th2.